Chemotherapy before surgery for HER2 positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two chemotherapy drugs, lobaplatin and carboplatin, given before surgery for HER2 positive breast cancer. The goal is to see if they are safe and help shrink the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have newly diagnosed breast cancer that is HER2 positive (a type of protein that helps cancer cells grow).
- Your cancer has not spread to distant parts of your body (stage IV).
- You have at least one tumor that can be measured by scans.
- Your heart, liver, kidneys, and blood counts are within acceptable levels.
- You agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.